Actimarbo 20 mg Flavoured Tablets for Dogs

Main information

  • Trade name:
  • Actimarbo 20 mg Flavoured Tablets for Dogs
  • Pharmaceutical form:
  • Tablet
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Actimarbo 20 mg Flavoured Tablets for Dogs
    Germany
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • marbofloxacin
  • Therapeutic area:
  • Dogs Non Food

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0461/002
  • Authorization date:
  • 26-06-2013
  • EU code:
  • UK/V/0461/002
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Issued:August2013

AN:00514/2012

Page1of6

SUMMARYOFPRODUCTCHARACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

Actimarbo20mgFlavouredTabletsforDogs(AT,CZ,DE,ES,IT,NL,PT,SK,UK)

Actimarbo20mgTabletsforDogs(FR)

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

Eachtabletcontains:

Activesubstance:

Marbofloxacin 20.0mgpertablet

Excipients:

Forafulllistofexcipients,seesection6.1.

3. PHARMACEUTICALFORM

Tablet.

Off-whitetobeigebrownspotted,rounduncoatedtabletembossed “MV”and“20”on

eithersideofbreaklineononesideandplainonotherside.

Thetabletscanbedividedintohalves.

4. CLINICALPARTICULARS

4.1Targetspecies

Dogs.

4.2Indicationsforuse,specifyingthetargetspecies

Fordogs,marbofloxacinisindicatedinthetreatmentof:

Skinandsofttissueinfectionscausedbysusceptiblestrainsoforganisms.

Urinarytractinfections(UTI)associatedornotwithprostatitisorepididymitiscaused

bysusceptiblestrainsoforganisms.

Respiratoryinfections,causedbysusceptiblestrainsoforganisms.

4.3Contraindications

Issued:August2013

AN:00514/2012

Page2of7

Marbofloxacinshouldnotbeusedindogsagedlessthan12months,orlessthan18

monthsforexceptionallylargebreedsofdogs,suchasGreatDanes,Briard,Bernese,

BouvierandMastiffs,withalongergrowthperiod.

Donotuseinanimalswithknownhypersensitivitytomarbofloxacinorother

(fluoro)quinolonesortoanyoftheexcipientsoftheproduct.

Donotuseincaseofconfirmedorsuspectedresistancetofluoroquinolones(cross

resistance).

Donotuseincats.Forthetreatmentofthisspecies,a5mgtabletisavailable.

4.4Specialwarningsforeachtargetspecies

AlowurinarypHcouldhaveaninhibitoryeffectontheactivityofmarbofloxacin.

4.5Specialprecautionsforuse

Specialprecautionsforuseinanimals

Thefluoroquinoloneshavebeenshowntoinduceerosionofarticularcartilageinjuvenile

dogsandcareshouldbetakentodoseaccuratelyespeciallyinyounganimals.

Somefluoroquinolonesathighdosesmayhaveanepileptogenicpotential.Cautious

useisrecommendedindogsdiagnosedassufferingfromepilepsy.

Fluoroquinolonesshouldbereservedforthetreatmentofclinicalconditionswhichhave

respondedpoorly,orareexpectedtorespondpoorlytootherclassesofantimicrobials.

Wheneverpossible,useoffluoroquinolonesshouldbebasedonsusceptibilitytesting.

UseoftheproductdeviatingfromtheinstructionsgivenintheSPCmayincreasethe

prevalenceofbacteriaresistanttothefluoroquinolonesandmaydecreaseeffectiveness

oftreatmentwithotherquinolonesduetothepotentialforcross-resistance.

Specialprecautionstobetakenbythepersonadministeringtheveterinary

medicinalproducttoanimals

Peoplewithknownhypersensitivityto(fluoro)quinolonesshouldavoidcontactwiththe

veterinarymedicinalproduct.

Incaseofaccidentalingestionseekmedicaladviceimmediatelyandshowthepackage

leafletorthelabeltothephysician.

Washhandsafteruse.

4.6Adversereactions(frequencyandseriousness)

Atthetherapeuticrecommendeddosage,nosevereside-effectsaretobeexpectedin

dogs.

Mildsideeffectssuchasvomiting,softeningoffaeces,modificationofthirstortransient

increaseinactivitymayoccasionallyoccur.Thesesignsceasespontaneouslyafter

treatmentanddonotnecessitatecessationoftreatment.

Issued:August2013

AN:00514/2012

Page3of7

Hypersensitivity(allergic)reactionsmayoccurintreatedanimals.Inthecaseofallergic

reaction,thetreatmentshouldbewithdrawn.

4.7Useduringpregnancy,lactationorlay

Studiesinlaboratoryanimals(rats,rabbits)showednoteratogenicity,embryotoxicity

andmaternotoxicitywithmarbofloxacinattherapeuticdoses.

Thesafetyofmarbofloxacinhasnotbeenassessedinpregnantandlactatingdogs.

Useonlyaccordingtothebenefit/riskassessmentbytheresponsibleveterinarianin

pregnantandlactatinganimals.

4.8Interactionwithothermedicinalproductsandotherformsofinteraction

Fluoroquinolonesareknowntointeractwithorallyadministeredcations(Aluminium,

Calcium,Magnesium,Iron).Insuchcases,thebioavailabilitymaybereduced.

Concomitantadministrationoftheophyllinerequirescarefulmonitoringasserumlevels

oftheophyllinemayincrease.

4.9Amountstobeadministeredandadministrationroute

Fororaladministration.

Therecommendeddoserateindogsis2mg/kg/d(1tabletfor10kgperday)insingle

dailyadministration.

Species Weight Dose(Numberoftabletsperday)

Actimarbo

5mgtablet Actimarbo

20mgtablet Actimarbo

80mgtablet

Dog ≤5kg

2 OR ½

5- ≤10kg 1

10- ≤15kg 1½

15- ≤20kg 2 OR ½

20- ≤25kg

25- ≤30kg 3

30- ≤35kg 3½

35- ≤40kg 4 OR 1

40- ≤60kg

60- ≤80kg 2

Toensureacorrectdosagebodyweightshouldbedeterminedasaccuratelyas

possibletoavoidunderdosing.

inskinandsofttissueinfections,treatmentdurationisatleast5days.Dependingon

thecourseofthedisease,itmaybeextendedupto40days.

Issued:August2013

AN:00514/2012

Page4of7

inurinarytractinfections,treatmentdurationisatleast10days.Dependingonthe

courseofthedisease,itmaybeextendedupto28days.

inrespiratoryinfections,treatmentdurationisatleast7daysanddependingonthe

courseofthedisease,itmaybeextendedupto21days.

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Overdosagemaycauseacutesignsintheformofneurologicaldisorders,whichshould

betreatedsymptomatically.

4.11Withdrawalperiod(s)

Notapplicable.

5. PHARMACOLOGICALPROPERTIES

Pharmacotherapeuticgroup:Antibacterialsforsystemicuse,Fluoroquinolones

ATCvetcode:QJ01MA93

5.1Pharmacodynamicproperties

Marbofloxacinisasynthetic,bactericidalantimicrobial,belongingtothefluoroquinolone

groupwhichactsbyinhibitionofDNAgyrase.Itiseffectiveagainstawiderangeof

Grampositivebacteria(includingStreptococciandinparticularStaphylococci)and

Gramnegativebacteria(Escherichiacoli,Enterobactercloacae,Proteusspp,

Klebsiellaspp,Shigellaspp,Pasteurellaspp,Pasteurellaspp,Pseudomonasspp)as

wellasMycoplasmaspp.

Marbofloxacinisnotactiveagainstanaerobes,yeastsorfungi.Casesofresistance

havebeenobservedinStreptococcus.

Themarbofloxacininvitroactivityagainstcanineandfelinepathogensisolatedin

Germanybetween2004and2006isgood:MIC

valuesare0.5µg/mlfor

Staphylococcuspseudointermedius,0.03µg/mlforEscherichiacoliand0.06µg/mlfor

Pasteurellamultocida .StrainswithMIC≤1µg/mlaresensitivetomarbofloxacin

whereasstrainswithMIC≥4µg/mlareresistanttomarbofloxacin.

Resistancetofluoroquinolonesoccursbychromosalmutationwith3mechanisms:

decreaseofbacterialwallpermeability,expressionofeffluxpumpormutationof

enzymesresponsibleformoleculebinding.

Therewasnosignificantdevelopment,evolutionorspreadofresistanceinpathogenic

strainsisolatedfromdiseasesincompanionanimals,sincetheuseofmarbofloxacinon

theveterinarymarket.Theincidenceandthedegreeoftransferofgeneticresistance

maybeconsideredasverylow.

Issued:August2013

AN:00514/2012

Page5of7

Cross-resistancetobeta-lactamantibiotics,aminoglycosides,tetracyclines,macrolides

andpolypeptideantibiotics,sulfonamides,nitrofuransanddiaminopyrimidinesgenerally

doesnotoccur.However,certainmutationscausingresistancetomarbofloxacin,can

alsocauseresistanceagainstcephalosporins,tetracyclines,macrolidesand

chloramphenicol.

5.2Pharmacokineticparticulars

Afteroraladministrationindogsattherecommendeddoseof2mg/kg,marbofloxacinis

readilyabsorbedandreachesmaximalplasmaconcentrationsof1.5µg/mlwithin2

hours.

Itsbioavailabilityiscloseto100%.

Itisweaklyboundtoplasmaproteins(lessthan10%),extensivelydistributedandin

mosttissues(liver,kidney,skin,lung,bladder,digestivetract)itachieveshigher

concentrationsthaninplasma.Marbofloxaciniseliminatedslowly(t½ß=14hindogs)

predominantlyintheactiveforminurine(2/3)andfaeces(1/3).

6. PHARMACEUTICALPARTICULARS

6.1Listofexcipients

Lactosemonohydrate

Cellulosemicrocrystalline

PovidoneK90

Purifiedwater

Crospovidone

Meatflavour

Silica,colloidalanhydrous

Magnesiumstearate

6.2Incompatibilities

Noneknown.

6.3Shelflife

Shelf-lifeoftheveterinarymedicinalproductaspackagedforsale:3years.

Shelf-lifeofhalvedtablets:7days.

Seealsosection6.4.

6.4.Specialprecautionsforstorage

Thisveterinarymedicinalproductdoesnotrequireanyspecialstorageconditions.

Issued:August2013

AN:00514/2012

Page6of7

Incaseofusinghalvedtablets:Returnanyremaininghalftablettotheopenedblister

pocket.Usetheremaininghalftabletforthenextadministration.

Seealsosection6.3.

6.5Natureandcompositionofimmediatepackaging

Theproductispackagedinaluminium –PVC/aluminium/polyamideblister.

Boxof1blisterof10tablets

Boxof2blistersof10tablets

Boxof10blistersof10tablets

Notallpacksizesmaybemarketed.

6.6Specialprecautionsforthedisposalofunusedveterinarymedicinal

productorwastematerialsderivedfromtheuseofsuchproducts

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuch

veterinarymedicinalproductsshouldbedisposedofinaccordancewithlocal

requirements.

7. MARKETINGAUTHORISATIONHOLDER

EcupharNV

Legeweg157-i

8020Oostkamp

Belgium

8. MARKETINGAUTHORISATIONNUMBER

Vm32742/4010

9. DATEOFFIRSTAUTHORISATION

August2013

10.DATEOFREVISIONOFTHETEXT

August2013

Issued:August2013

AN:00514/2012

Page7of7

PROHIBITIONORSUPPLYSALEANDORUSE

Onveterinaryprescriptiononly.

APPROVED 2/08/13

4-12-2018

FDA Approves Pexion for Treating Noise Aversion in Dogs

FDA Approves Pexion for Treating Noise Aversion in Dogs

The U.S. Food and Drug Administration announced today that its Center for Veterinary Medicine has approved Pexion (imepitoin tablets) to treat noise aversion in dogs. Dogs with noise aversion are sensitive to loud noises such as fireworks, street/traffic noises, and gun shots.

FDA - U.S. Food and Drug Administration

21-11-2018

Fresenius Kabi Issues Voluntary Nationwide Recall of Sodium Chloride Injection, USP, 0.9% Due to Product Labeling Incorrectly Stating Stoppers Do Not Contain Latex

Fresenius Kabi Issues Voluntary Nationwide Recall of Sodium Chloride Injection, USP, 0.9% Due to Product Labeling Incorrectly Stating Stoppers Do Not Contain Latex

Fresenius Kabi USA is voluntarily recalling 163 lots of Sodium Chloride Injection, USP, 0.9%, 10 mL fill in a 10 mL vial and Sodium Chloride Injection, USP, 0.9%, 20 mL fill in a 20 mL vial to the user level. The product insert states that stoppers for both the 10mL and the 20mL vials do not contain natural rubber latex; the tray label for the two vial sizes and the vial label for the 20mL vial also state that the stoppers do not contain latex. The product is being recalled because the stoppers contain n...

FDA - U.S. Food and Drug Administration

20-11-2018

November 20, 2018: Rochester Man Pleads Guilty to Smuggling Counterfeit Cialis and Viagra into the United States

November 20, 2018: Rochester Man Pleads Guilty to Smuggling Counterfeit Cialis and Viagra into the United States

November 20, 2018: Rochester Man Pleads Guilty to Smuggling Counterfeit Cialis and Viagra into the United States

FDA - U.S. Food and Drug Administration

24-10-2018

G & C Raw, LLC is Expanding Recall to Include All Product Lots Manufactured from February 27, 2018 Through July 20, 2018, Because of Possible Listeria Monocytogenes Health Risk

G & C Raw, LLC is Expanding Recall to Include All Product Lots Manufactured from February 27, 2018 Through July 20, 2018, Because of Possible Listeria Monocytogenes Health Risk

G & C Raw, of Versailles, OH is recalling all products lots manufactured from February 27, 2018 through July 20, 2018, as a precaution because they have the potential to be contaminated with Listeria monocytogenes

FDA - U.S. Food and Drug Administration

22-6-2018

June 20, 2018: Fitchburg Woman and Saugus Man Sentenced for Roles in Counterfeit Steroid Conspiracy

June 20, 2018: Fitchburg Woman and Saugus Man Sentenced for Roles in Counterfeit Steroid Conspiracy

June 20, 2018: Fitchburg Woman and Saugus Man Sentenced for Roles in Counterfeit Steroid Conspiracy

FDA - U.S. Food and Drug Administration

2-5-2018

April 17, 2018: Tampa Resident Sentenced to More Than 20 Years in Federal Prison for Tricare Health Care Fraud Scheme

April 17, 2018: Tampa Resident Sentenced to More Than 20 Years in Federal Prison for Tricare Health Care Fraud Scheme

April 17, 2018: Tampa Resident Sentenced to More Than 20 Years in Federal Prison for Tricare Health Care Fraud Scheme

FDA - U.S. Food and Drug Administration

26-11-2018

Data show that nearly 20% of current 510(k)s are cleared based on a predicate that’s more than 10 years old. That doesn’t mean the products are unsafe. But it does mean that some devices may not be continually improving, which is the hallmark of health te

Data show that nearly 20% of current 510(k)s are cleared based on a predicate that’s more than 10 years old. That doesn’t mean the products are unsafe. But it does mean that some devices may not be continually improving, which is the hallmark of health te

Data show that nearly 20% of current 510(k)s are cleared based on a predicate that’s more than 10 years old. That doesn’t mean the products are unsafe. But it does mean that some devices may not be continually improving, which is the hallmark of health technologies.

FDA - U.S. Food and Drug Administration

4-9-2018

Agenda:  Agenda - CHMP agenda of the 20-23 August 2018 written procedure

Agenda: Agenda - CHMP agenda of the 20-23 August 2018 written procedure

Agenda of CHMP written procedure*20-23 August 2018

Europe - EMA - European Medicines Agency

22-8-2018

After over 20 years of wearing contact lenses, this freelance blogger had an unexpected diagnosis in her left eye:  http://bit.ly/2h2NcHz .pic.twitter.com/ecJErFeiSH

After over 20 years of wearing contact lenses, this freelance blogger had an unexpected diagnosis in her left eye: http://bit.ly/2h2NcHz .pic.twitter.com/ecJErFeiSH

After over 20 years of wearing contact lenses, this freelance blogger had an unexpected diagnosis in her left eye: http://bit.ly/2h2NcHz . pic.twitter.com/ecJErFeiSH

FDA - U.S. Food and Drug Administration

20-7-2018

Agenda:  Agenda - CAT agenda of the 18-20 July 2018 meeting

Agenda: Agenda - CAT agenda of the 18-20 July 2018 meeting

Committee for Advanced Therapies (CAT) agenda for the meeting on 18-20 July 2018

Europe - EMA - European Medicines Agency

29-6-2018

A past diagnosis of asthma is also associated with #COPD in 20% of the cases. Visit  https://bit.ly/1xErH2t  to learn more. #FactFridaypic.twitter.com/JWK672XtdI

A past diagnosis of asthma is also associated with #COPD in 20% of the cases. Visit https://bit.ly/1xErH2t  to learn more. #FactFridaypic.twitter.com/JWK672XtdI

A past diagnosis of asthma is also associated with #COPD in 20% of the cases. Visit https://bit.ly/1xErH2t  to learn more. #FactFriday pic.twitter.com/JWK672XtdI

FDA - U.S. Food and Drug Administration